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Combinatorial silencing of more than one protein via small interfering RNA (siRNA) is a new strategy that can
enhance the effect of RNA interference on cell function. To explore this strategy, we selected JAK/STAT axis as a
major signaling pathway that contributes to several mechanisms involved in cancer cell proliferation and sur
vival. We focused on four proteins involved in this pathway to explore the possibility of identifying a combi
natorial targeting strategy (as the proof of concept) with enhanced efficiency: gp 130 (a co-receptor for IL6
cytokines), JAK2, STAT3, and importin α3 (the nuclear transporter reportedly involved in translocation of
activated STAT3 to nucleus). Selected proteins were targeted by siRNA in two selected Triple Negative Breast
Cancer cell lines (MDA-MB-231 and MDA-MB-468). The effect of individual and selected combinations of siRNAs
on selected downstream antiapoptotic proteins, pro-apoptosis proteins, and cell-cycle regulating proteins was
explored. Combinatorial silencing of JAK2/gp 130 enhanced the effect of RNA interference on downstream
proteins significantly, and demonstrated enhanced effect in reducing cell viability, cell migration, and the level of
activation of STAT3. In conclusion, the promising results of simultaneous targeting of JAK2 and gp 130 might be
an example for potential combinatorial silencing strategies in cancer treatment.
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1. Introduction
RNA interference (RNAi) is a potentially powerful tool that can
specifically target the expression of virtually any protein without the
expensive and time-consuming drug development studies. This strategy
entered a new era in August of 2018 with the Food and Drug Adminis
tration (FDA) approval of patisiran (Onpattro®, Alnylam Pharmaceuti
cals), which addresses a hereditary disorder affecting the liver (Wood,
2018). On the other hand, the introduction of Clustered Regularly
Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated
protein (Cas)9 created in a new excitement and a new turning point for
protein silencing, when the first clinical studies on CRISPR gene editing
was performed in 2016 by injecting engineered T cells to a patient with
metastatic non-small cell lung cancer (Cyranoski, 2016), and the 2020
Nobel Prize in Chemistry was awarded to CRISPR/Cas9 research.
While combination of anticancer drugs is a stablished practice in
cancer treatment, due to limited use of RNA interference in clinics,
combinatorial silencing of different proteins has not been a common
practice. In fact, a quick search in Clinicaltrials.gov shows 25 clinical
studies in different stages (in progress, withdrawn, or completed), none
of which is exploring the combinatorial silencing of more than one
protein (however, NCT01676259 is a phase II study recruiting pancre
atic cancer patients to study a combination of siRNA targeting KRAS
G12D and chemotherapy (Varghese et al., 2020), and NCT04995536 is a
phase I study recruiting patients with relapsed or refractory B-Cell
Non-Hodgkin Lymphoma to study the combination of siRNA targeting
signal transducers and activators of transcription 3 (STAT3) and radio
therapy (Yu et al., 2022)). In our previous studies, we have reported
potential beneficiary effect of combining siRNAs targeting Mcl-1 and
P-glycoprotein (Aliabadi et al., 2013a) and Mcl-1 and Ribosomal Protein
S6 Kinase A5 (RPS6KA5) (Aliabadi et al., 2016; 2013b) in MDA-MB-231
cells, and have reviewed the recent efforts in this area and the future of
combinational therapy using nucleic acid therapeutics (Bahadur et al.,
2017). Here, we selected a specific signaling axis and well-known pro
teins to explore the potential of siRNA silencing in identifying promising
combinational therapies in triple negative breast cancer cells as a model
cell. However, the principals of this project could potentially apply to
other targets, signaling pathways, and cancer cell types.
Janus tyrosine kinase (JAK)/STAT signaling pathway is one of major
signaling cascades that contributes to proliferation and survival of
cancer cells (Bousoik and Montazeri Aliabadi, 2018). Specifically, JAK2
and STAT3 have been extensively studied for their role in this pathway,
and for their crosstalk with other major intracellular signaling path
ways. JAK is a family of four kinases (JAK1, JAK2, JAK3, and TYK2)
associated with cytoplasmic domain of cytokine receptors (Behrmann
et al., 2004). Binding of ligands to cytokine receptors triggers trans
phosphorylation of partner JAK in the dimer. JAK activation, however,
is triggered by more than just cytokine receptors and includes a wide
variety of receptors, including receptor tyrosine kinases (RTKs) (Bou
soik and Montazeri Aliabadi, 2018). This activation results in recruit
ment of STATs, which are phosphorylated and transported to nucleus.
STATs are also a family of proteins that contain seven members: STAT1,
STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6 (Aittomaki and Pesu,
2014; Rawlings et al., 2004). Recruitment and activation of different
members of STAT family of proteins results in transcription of different
proteins, which in turn result in different outcomes (Fig. 1).
Triple-negative breast cancer (TNBC), hallmarked by lack of
expression of estrogen receptor (ER), progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER-2), accounts for only
15–20% of all breast cancers (Le Gallo et al., 2018); however, compared
to other subtypes, TNBC is more likely to recur and has a median overall
survival of approximately 1 year vs. approximately 5 years for the other
subtypes (Waks and Winer, 2019). Currently, there are no molecularly
targeted drugs towards JAK/STAT pathway that are approved by FDA

Fig. 1. A schematic presentation of gp 130/JAK2/STAT3 signaling pathway.
Binding of cytokines in interleukin 6 (IL6) family to gp 130 co-receptor leads to
phosphorylation of JAK2 and STAT3 proteins. The latter dimerizes, translocates
into the nucleus, and regulates the expression of cell cycle regulators and antiand pro-apoptotic proteins.

for breast cancer therapy; however, many clinical trials have been
conducted, are recruiting, or underway that concentrate on targeting
this signaling pathway. A recent phase 2 clinical trial in patients with
HER-2-negative breast cancer showed a positive impact for adding
ruxolitinib (a pan JAK inhibitor with more selectivity toward JAK1 and
2 (Dymock and See, 2013), mostly used in myeloproliferative neo
plasms) to capecitabine (an antimetabolite) in terms of overall response
rate; however, the overall survival rate and progression-free survival
were not improved significantly (O’Shaughnessy et al., 2018). A phase 1
clinical trial on TTI-101 (an oral STAT3 inhibitor) in different types of
advanced cancers (including breast cancer) is currently recruiting
(NCT03195699 (Oral STAT3 Inhibitor, 2021)). However, like many
other molecularly targeted drugs, JAK/STAT inhibitors are also plagued
by rapid resistance development (genetic and functional), which high
lights the importance of exploring combined therapy options (Meyer,
2017).
We recently reported a study exploring molecular mechanisms
involved in inherent and acquired resistance against ruxolitinib, which
showed promising results for combined targeted protein silencing to
overcome resistance against this JAK inhibitor (Bousoik et al., 2019). In
this study, we explored a systematic approach in silencing selected
targets within JAK/STAT signaling cascade in breast cancer cells, to
evaluate combinatorial targeting of multiple proteins in the same
pathway. The selected targets included: gp 130, JAK2, STAT3, and
importin α3. Also known as Interleukin 6 signal transducer (IL6ST), gp
130 is a co-receptor for the family of IL6 cytokines, including, but not
limited to (IL-11), leukemia inhibitory factor (LIF), oncostatin M (OSM),
ciliary neurotrophic factor (CNTF), and cardiotrophin-1 (CT-1) (Omo
kehinde and Johnson, 2020). Activation of gp 130 by the ligands
included in IL-6 family results in the activation of all three major
downstream pathways, including JAK/STAT pathway (Stahl et al.,
1994). IL-6/gp 130/JAK2 signaling pathway has been specifically
implicated in TNBC development (Berishaj et al., 2007). On the other
hand, while translocation between cytoplasm and nucleus is a routine
process, the nuclear envelope is a barrier especially for large molecules
(> 40,000 – 60,000 Daltons); therefore, activated (phosphorylated and
2
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dimerized) STATs usually require a specific transport receptor for
facilitated transport (Hulsmann et al., 2012). These receptors are
generally known as importins with subunits α and β (Gorlich and Mattaj,
1996). Involvement of specific importins in nuclear translocation of
specific members of STAT family is subject of debate (Bousoik and
Montazeri Aliabadi, 2018). However, Liu et al. reported specificity of
importin α3 (Karyopherin Subunit Alpha 4; KPNA4) for translocation of
STAT3 in 2005 (Liu et al., 2005), and we selected this importin based on
their report.

FAB10951F), gp130 (Catalog No FAB228F), and IL2R (Catalog No
FAB2842F) were purchased from R&D systems. Primary antibodies for
western blotting included anti-gp130 monoclonal mouse IgG1 (Catalog
No MAB2281), anti-PTEN monoclonal mouse IgG1 (Catalog No
MAB847), anti-Mcl-1 monoclonal mouse IgG1 (Catalog No MAB828),
anti-Bcl2 monoclonal mouse IgG2B (Catalog No MAB8272), anti-P53
monoclonal mouse IgG2B (Catalog No MAB1355), anti-Cyclin D1
monoclonal mouse IgG1 (Catalog No MAB4314), anti-Histone H3
monoclonal rabbit IgG (used as the nuclear marker and paired with antirabbit secondary antibody; Catalogue No MAB9448), and anti-mouse
secondary antibody (Catalog No HAF007) that were obtained from
R&D systems. Monoclonal antibodies for anti-STAT3 monoclonal mouse
IgG2A (Catalog No mAb 9139, detecting total STAT3 and paired with the
anti-mouse secondary antibody), anti-pSTAT3 monoclonal rabbit IgG
(mAb 94,994, detecting STAT3 phosphorylated at Ser727), anti-B-actin
monoclonal mouse IgG2B (Catalog No 3700S, paired with the anti-mouse
secondary antibody), anti-JAK2 monoclonal rabbit IgG (Catalog No
3230S), anti-Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
monoclonal mouse IgG1 (as cytoplasmic marker and paired with the
anti-mouse secondary antibody; Catalogue No 97,166), and anti-rabbit
secondary antibody (Catalog No 7074S) were obtained from Cell
Signaling technology (Beverly, MA). All western blot equipment and
reagents were obtained from Bio-Rad Laboratories (Hercules, CA). All
other materials were obtained from Fisher Scientific (Carlsbad, CA).

2. Methods
2.1. Materials
MDA-MB-231 (ATCC® HTB-26™), MDA-MB-231, KRas-CRM
(MDA231K; MDA-MB-231, certified for KRas mutation; ATCC® CRMHTB-26™), MDA-MB-468 (ATCC® HTB-132™), MCF7 (ATCC® HTB22™), and AU565 (ATCC® CRL-2351™) human breast cancer cell lines
were purchased from American Type Culture Collection (ATCC; Mana
ssas, VA). Dulbecco’s modified Eagle’s medium (DMEM; low glucose
with L-glutamine), RPMI 1640, Lipofectamine® 2000 reagent, Recov
ery™ Cell Culture Freezing Medium (Catalogue number: 12,648,010),
and Opti-MEM medium (Reduced serum medium) were provided by
Thermo Fisher Scientific (Carlsbad, CA). Penicillin (10,000 U/mL),
streptomycin (10 mg/mL), fetal bovine serum (FBS), and Hank’s
Balanced Salt Solution (HBSS) were provided by Life Technologies
(Grand Island, NY). Flow cytometry staining buffer was purchased from
R&D System (Minneapolis, MN). Scrambled negative control siRNA
(Catalog No AM4620) was obtained from Ambion (Austin, TX). JAK2
siRNA (Catalog No SI02659657), gp130 siRNA (Catalog No
SI00033719), STAT3 siRNA (Catalog No SI00048363), and Importin
alpha3 siRNA (Catalog No SI04142726) were purchased from Qiagen
(Valencia, CA). All the primers were designed and ordered from Inte
grated DNA Technologies (IDT; Coralville, IA), and the sequences are
summarized in Table 1. PCR master mixes (iScript™ Reverse tran
scription Supermix and iTaq Universal SYBR Green Supermix) were
supplied by Bio-Rad (Hercules, CA). Cell Counting Kit-8 (CCK-8) assay
was purchased from Biotool (Houston, TX). TRIzol™ reagent was pur
chased from Sigma (St. Louis, MO). BCA protein assay kit was purchased
from Thermo scientific (Rockford, IL). Fluorescein antibodies for flow
cytometry included CXCR4 (Catalog No FAB170F), Leptin R (Catalog No
FAB867F), Epithelial growth factor receptor (EGFR; Catalog No

2.2. Cell lines
All cell lines were stocked in freezing medium and maintained in
liquid nitrogen in multiple cryogenic vials before being thawed for ex
periments. TNBC cell lines MDA-MB-231, MDA-MB-231 K, and MDAMB-468 cells were cultured in DMEM medium supplemented with
100 units/ml penicillin, 100 µg/ml streptomycin and 10% (v/v) fetal
bovine serum (FBS) and were trypsinized (using a 0.05% solution of
trypsin) regularly for passage, when reached 80 – 100% confluency.
AU565 (HER+ and expected to express EGFR) and MCF7 cells (estrogen
and progesterone-positive and expected to express HER2 and EGFR)
were cultured in RPMI medium with similar supplements and passage
conditions. Cells were maintained in incubators adjusted for 37 ◦ C,5%
CO2, and 95% humidity. New cell population were thawed and used
when any cell population reached 40 passages.
2.3. Protein silencing via siRNA
For any given protein silencing experiment, we included a “no
treatment” (NT) group for cells receiving normal saline, as a negative
control. We also matched any silencing effort with cells receiving
scrambled siRNA (Control siRNA or CsiRNA) delivered with same carrier
and with the exact same concentration. Cells were seeded into six-well
culture plates with antibiotic free DMEM medium at ⁓ 4 × 105 cells/
mL (1.5 ml per well). After 24 h of incubation in 37 ◦ C and 5% CO2,
siRNA transfection was carried out using Lipofectamine® 2000 reagent
based on manufacturer’s guidelines. Briefly, Lipofectamine® 2000 was
diluted with Opti-MEM medium in 1:100 ratio. Opti-MEM medium was
also used to dilute 10 nM siRNA at ratio 1:50. After five minutes, diluted
siRNA was mixed with Lipofectamine® 2000 reagent in one tube and
incubated for 20 min at room temperature to allow carrier-siRNA
complexes to form. Then, 500 µl of the complex solution was added to
each well after removing the growth medium. Cells were incubated at 37
◦
C in 5% CO2 incubator for 6 h, after which, the medium containing
complexes was removed and replaced by antibiotic free DMEM medium,
and the plates were returned to the incubator for the total incubation
time of 72 h. For combinational silencing, Lipofectamine®/siRNA
complexes was prepared by adding mixture of two siRNAs for two
selected targets, each contributing half of the final concentration. The
groups representing single target silencing included in these experi
ments was performed with a mixture of scrambled siRNA and the target

Table 1
The sequence of forward and reverse primers designed for analysis of the mRNA
expression level of proteins of interest.
Targets

Reverse sequence

Forward sequence

gp130
JAK2

GTG ACC ACT GGG CAA TAT GA
TCG AAA TTG GGC CAT GAC A

STAT3

ACA ACA TGT CAT TTG CTG
AAA TCA
TGC TGG GAAGTG TGA AAG AG

GGG AGT GCT GTT CTG CTT TA
AAC TGC AGA TGC ACA TCA
TTA CCT
TCC TTG GGA ATG TCA GGA
TAG AG
TCA GCC ACC AGG AAG TTA
AAG
TGT GGC GGG ACT CTT TAT
GGG AAG GGA CAG AAG ATG A
AGG ATG GGT TGC CAT TGA T

Importin
α3
PTEN
p53
BCL-XL
BCL-2
Mcl-1
Cyclin D1
CDK4
FAK
B-Actin
HPRT1

GGC TCA ACT CTC AAA CTT CC
CAG ATG AAG CTC CCA GAA TG
GGA TAC AGC TGG AGT CAG
TTT A
TCA CTT GTG GCC CAG ATA
CGA GAA CGT CTG TGA TAC
TTT CTG
GAG GGC GGA TTG GAA ATG A
AGA TAC AGC CAA CAC TCC AC
GCT GCA GGA TCT GGT TTA
GAC CAA AAG CCT TCA TAC
ATC TCA
AGG AAT GCA GCA ACT GAC

GCG GCC TCT GTT TGA TTT
CCT TTG TGG CTA AAC ACT
TGA AG
GCG GAG GAG AAC AAA CAG
AT
GCT ACC AGA TGG CAC TTA CA
CTC TCT CGA GGC AGT ATT GA
CAC ACA GGG GAG GTG ATA
GC
TCT GTG GCC ATC TGC TTA
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specific siRNA for comparison purposes. For example, in comparing
individual silencing of JAK2 or gp130 with JAK2/gp130 combinatorial
silencing, we used JAK2 siRNA + scrambled siRNA, gp130 siRNA +
scrambled siRNA, and JAK2 siRNA + gp130 siRNA, keeping the con
centration of each siRNA the same for all study groups.

2.7. Western blot analysis
Protein expression of selected targets were analyzed by Western blot.
Cell protein lysates were prepared according to standard protocol using
RIPA buffer. Briefly, treated and transfected cells were collected by
trypsinization, and the cell suspension was centrifuged at 800 RPM for 5
min. Then the supernatant was discarded, and the cell pellet was washed
three times with ice cold PBS and then 200 µl of RIPA buffer was added
to 25 µl of cell pellet and pipetted up and down. The cell lysates were
then incubated on ice for one hour, after which the tubes were centri
fuged at 12,000 g for 10 min. The supernatant was transferred to precooled tubes, and Total protein concentration was determined using
BCA assay according to standard protocol. Briefly, 200 µl of work re
agent (50:1 A:B) was added to 25 µl of standard and unknown sample in
triplicate into a microplate well, plated was mixed on plate shaker for
30 s then it was incubated at 37 ◦ C in 5% CO2 for 30 mins. Then the
absorbance was measured at 562 nm using microplate reader (Spec
traMAX M5 microplate reader). Protein (23–30 μg) was loaded per well
of a 12% SDS PAGE gel using electrophoresis buffer (0.192 M glycine,
25 mM Tris, 0.1% SDS). After electrophoresis, the gel was transferred
onto a PVDF membrane (Catalog No. 170–4272) using transfer buffer
(0.192 M glycine, 25 mM Tris, 0.025% SDS, 10% methanol). Mem
branes were blocked in TBS-T with 5% non-fat dry milk and incubated
overnight with the primary anti-body (1:1000). Then, the membrane
was washed with TBST three times five mins for each time. Then the
membrane was incubated with secondary HRP-linked antibody
(1:1000). Then the washing step was repeated. Detection was done by
ECL Detect Kit using ChemiDoc imager (Bio-Rad).
For evaluation of differential nuclear and cytoplasmic protein
expression levels, cells were pelleted at 2000 rpm for 5 min. After
removing the supernatant, the cells were resuspended in Dounce buffer
containing protease inhibitors. The cell suspension was incubated on ice
for 15 min, before it was spiked with cold 10% NP-40 and vortexed for
10 s. The suspension was centrifuged at 10,000 rpm for 10 min at 4 ◦ C to
pellet the nuclei. Supernatant was isolated for cytoplasmic extraction.
The nuclear pellet was washed in cold PBS twice and centrifuged to
remove the supernatant. The isolated nuclei were then lysed using RIPA
buffer containing protease inhibitors.

2.4. Cell viability
The effects of individual and combinational silencing on MDA-MB468 and MDA-MB-231 cell viability was determined using CCK-8
assay kit in accordance with the manufacturer’s instructions. Briefly,
cells were plated and transfected as described. Cell proliferation was
determined at 24, 48 and 72 h after treatment, with addition of 10 µl of
CCK reagent to each well. The absorbance of each well was measured
using a microplate reader (SpectraMAX M5 microplate reader) at 450
nm. The results were normalized to non-treated cells (considered 100%
viable) after subtracting the reading from blank plates (medium without
cells in three wells with CCK-8 solution added). Each experiment was
performed in triplicate.
2.5. Flow cytometry
The expression of selected receptors was evaluated by exposing the
cells to Fluorescein amidite (FAM)-labeled antibody for the receptors of
interest, and the fluorescence signal was measured by flow cytometry
(BD-FACSVerse; BD Biosciences; San Jose, CA), using FITC channel to
quantify cell-associated fluorescence. MDA 231 and MDA 468 cells were
seeded at a density of 7 × 105 cells in T-25 flasks for 24 h. The cells
were trypsinized and collected, washed with HBSS, and then re-suspend
in 10 ml of staining Buffer. 400 µl of the suspension was transferred to a
small tube and 5 µl of antibody was added to it. Three tubes were pre
pared for each antibody, and three tubes for non-treated cells. The Tubes
were incubated in 4 ◦ C for 30 min. After incubation time, tubes were
centrifuged, and the supernatant was discarded. Cells were washed with
HBSS to remove unbound antibody and fixed by addition of 400 µl of
3.7% formaldehyde to each tube. After each flow cytometry analysis, the
percentage of cells with fluorescence signal and the mean fluorescence
of the cell population were calculated based on the calibration of the
signal gated with non-treated cells (as the negative control), so that the
auto-fluorescence would be ~ 1% of the population.

2.8. Scratch test
The effects of individual and combinational silencing on MDA-MB468 and MDA-MB-231 cell migration was examined by scratch migra
tion assay. The cells were transfected with scrambled control or targeted
siRNA and allowed to form a monolayer for 24 h after treatment. A
linear scratch wound was created on the monolayer using a 1000 µL
pipette tip, and the non-adherent cells were washed off with HBSS. OptiMEM medium (Reduced serum medium) was used following to wash to
minimize the contributions of cell proliferation. Cells were then incu
bated at 37 ◦ C in 5% CO2. Each scratch was randomly photographed at
two separate sites along the length of the scratch at 0, 24 and 48 h after
the scratch injury. The images were captured at 2 × magnification
(Keyence fluorescence microscope) and analyzed using Imager J soft
ware. Data are presented as the percentage of the closure area, indi
cating the degree of cells migrating into the scratch area.

2.6. Real-time PCR
RNA was extracted from cells using TRIzol™ reagent following the
manufacturer’s instructions. Briefly, one mL of TRIzol™ reagent was
added for each 1 × 106 cells. The cell lysates were incubated at room
temperature for 5 min, before chloroform (with a 1:5 v/v ratio to TRI
zol™) was added to the lysates. The tubes where mixed and incubated
for 2–3 min at room temperature, before the aqueous phase was
collected. Isopropanol was added to precipitate and pellet RNA using
centrifuge (12,000 g for 10 min in 4 ◦ C). The pellet was then washed
with 75% ethanol, and extracted RNA was then dissolved in RNase-free
water. The total extracted RNA in each sample was determined by
BioSpec-Nano (Shimadzu, Columbia, MD). In order to synthesize the
cDNA, 0.5 - 1 µg RNA was reverse transcribed using iScript™ reverse
transcription supermix and the C1000 Touch® thermocycler (Bio-Rad,
Hercules, CA), following the manufacturer’s guidelines. A CFX96TM
optical module (Bio-Rad, Hercules, CA) was used for RT-PCR analysis,
where human β-actin was used as the endogenous gene to normalize the
mRNA level of targeted proteins. RT-qPCR was conducted using iTaq
universal SYBR green Supermix kit. Cycling conditions were as follows;
95 ◦ C for 2 min, followed by 40 cycles of denaturation 95 ◦ C for 5 s and
annealing temperature 55 ◦ C for 30 s, and a final extension step at 65 ◦ C
for 5 s. Analysis was performed by calculating ΔΔCT and relative
quantity (RQ).

2.9. Statistical analysis
All experiments were done in triplicates, and the data in graphs are
presented as mean ± standard deviation. The intergroup comparisons
were performed using one-way ANOVA and Tukey post-hoc test (p <
0.05) and GraphPad Prism 9.3.0 software.

4

E. Bousoik et al.

European Journal of Pharmaceutical Sciences 175 (2022) 106233

The aim of this study was to explore the JAK/STAT silencing in TNBC
cells, and AU565 and MCF7 cells were added as controls to evaluate the
receptor expression, and the results are summarized in Fig. 2. As ex
pected, EGFR expression was more prominent in AU565 and MCF7 cell
lines compared to TNBC cell lines (MDA-231, MDA-231 K, and MDA468). Among selected receptors, gp 130 was the only receptor that
was expressed in the majority (> 50%) of the TNBC cell line populations
(with approximately 64, 51 and 59% cells expressing gp 130 in MDA231 K, MDA-231, and MDA-468 cells, respectively). On the other hand,
IL2R showed the lowest level of expression in TNBC cells compared to
the control cell lines. The expression of CXCR4 and Leptin receptor
varied among the selected cell lines: While expression of both receptors
was higher in AU565 cells compared to all other cell lines, a significant
difference in expression level of Leptin R was not observed among other
selected cell lines. Also, expression of CXCR4 in TNBC cell lines MDA231
K and MDA468 was not significantly different than MCF7 cells. Based on
these results, gp130 was selected as the cell membrane receptor to
include in this study.

3. Results and discussion
3.1. Receptor expression level
JAK/STAT pathway is activated by a variety of cell membrane re
ceptors. Therefore, to select the upstream target for this study, we
explored the expression level of selected receptors with a reported role
in breast cancer (Bousoik and Montazeri Aliabadi, 2018) in a small panel
of breast cancer cells: (i) CXCR4: G protein-coupled receptors are one of
categories of receptors that were reported to activate JAK/STAT
pathway (Wagner and Siddiqui, 2012). Among G-protein-Coupled Re
ceptors (GPCRs), involvement of CXCR4 in breast cancer cell growth has
been reported. Chemokine stromal cell-derived factor (SDF-1alpha) can
activate CXCR4, which activates JAK2 and JAK3 kinases, which in turn
recruit and phosphorylate multiple STAT family members (Vila-Coro
et al., 1999). CXCR4 has also reported as a prognostic marker in a variety
of cancers, including breast cancer (Mukherjee and Zhao, 2013); (ii)
Leptin receptor (Leptin R): A type I cytokine receptor, Leptin R activa
tion (triggered by binding of leptin) activates JAK2, STAT3, and MAPK
extracellular signal-activated kinase 1/2 (ERK1/2) (Mullen and Gonza
lez-Perez, 2016). Leptin R signaling is well-studied in breast cancer, and
additionally enhances angiogenesis via overexpression of vascular
endothelial growth factor (VEGF) (Cirillo et al., 2008); (iii) EGFR: A
receptor tyrosine kinase (RTK), EGFR is one of most important cell
membrane receptors involved in activating multiple signaling pathways.
A role for EGFR in activating STAT proteins has been reported for more
than twenty-five years (Ueno et al., 1997); however, JAK-dependent
STAT3 activation by EGFR was reported in 2004 (Andl et al., 2004),
and has been confirmed in multiple reports ever since. RTKs have a
well-studied role in proliferation of breast cancer cells; iv) IL-2 receptor
(IL2R): Activation of IL-2R has been associated with activation of JAK1,
2, and 3, and STATs 1, 3, and 5 (Friedmann et al., 1996). IL-2R has an
important role in development of breast cancer and a correlation be
tween the expression of this receptor and the malignancy of the tumor
has been reported (Garcia-Tunon et al., 2004); and v) gp 130: As
mentioned in the introduction, activation of gp 130 co-receptor by IL-6
family of cytokines results in JAK/STAT activation and the role of this
pathway in TNBC is reported.

3.2. Individual and combinatorial silencing of the selected proteins
The silencing efficiency was evaluated for individual siRNA delivery
(combination of target-specific and scrambled siRNA vs. selected com
binations, and the results are summarized in Fig. 3A and B and Sup
plementary Tables 1 and 2. Among siRNAs used, the silencing efficiency
was lowest for JAK2 siRNA in MDA231 cells (approximately 0.5 relative
quantity for individual or combinational silencing). However, the same
siRNA was more efficient in MDA468 cells (0.09 – 0.32 relative quan
tity). Other siRNAs showed significant silencing efficiency in both cell
lines, with 0.32 relative quantity for importin α3 siRNA in MDA231 cells
after JAK2/Importin α3 combinational silencing as the lowest drop in
mRNA expression of a targeted protein.
Overall, combination of two targeted siRNAs did not increase the
silencing efficiency for any of the selected targets. It is noteworthy that
silencing JAK2 did not affect the mRNA levels of any other selected
protein in the pathway, including STAT3. This is, however, expected, as
JAK2 recruits and activates STAT3, and is not reported to directly in
crease the expression level of this downstream protein. Therefore, to

Fig. 2. The expression of selected receptors (CXCR4, Leptin R, EGFR, IL2R gamma, and gp130) on cell membrane of selected breast cancer cell lines. gp130 was the
only receptor that is overexpressed in selected triple negative breast cancer (TNBC) cell lines, MDA 231wild type (WT), MDA 231 K, and MDA 468 cell lines. The
expression of the receptors was detected using fluorescent-labeled monoclonal antibodies to the selected receptors and flow cytometry. Asterisks indicates significant
difference to non-TNBC cell lines (one-way ANOVA, Tukey post-hoc test; p<0.05). Bar graph represents the mean values (n = 4), and the error bars show the
standard deviation.
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Fig. 3. Individual and combinatorial silencing of the selected proteins in JAK/STAT pathway. The silencing efficiency was evaluated at mRNA level using Real-Time
PCR for individual silencing (combination of target-specific and scrambled siRNA) vs. selected combinations in MDA231 (A) and MDA468 cells (B). JAK2 siRNA
showed the lowest silencing efficiency in all study groups in MDA231 cells. Combination of JAK2 siRNA with other selected siRNAs (gp 130, STAT3, or importin α3)
did not increase the silencing efficiency on any of the selected targeted proteins. Bar graphs represent the mean values (n = 3), and the error bars show the stan
dard deviation.

study the effect of combinatorial silencing we explored some of the
proteins that are regulated by STAT3.

Supplementary Table 3). However, the mRNA level of Mcl-1 was
decreased to 58% compared to no treatment (NT) group. This was
somewhat unexpected as a reduction in expression of Bcl-2 levels has
been previously reported in Hep2 cells (Gao et al., 2005). While we
expected a downregulation in Bcl-2 and Bcl-XL mRNA levels as well, a
similar pattern was observed for silencing of importin α3. Individual
silencing of Jak2 showed minimal effect on expression of the selected
antiapoptotic proteins and silencing gp130 alone showed a moderate
effect on all three mRNA levels (63, 77, and 76% mRNA levels compared
to NT group for Bcl-2, Bcl-XL, and Mcl-1, respectively). More interest
ingly, while combination of JAK2 siRNA with STAT3 or importin α3 did
not show any effect in lowering the mRNA level of either of the anti
apoptotic proteins in this cell line, JAK2/gp130 silencing showed a
significant downregulation in mRNA level of all three selected proteins
(44, 33, and 44% mRNA levels for Bcl-2, Bcl-XL, and Mcl-1, respectively;
Fig. 4A and Supplementary Table 3).
Similar experiment in MDA468 cells showed a more significant

3.3. Downstream proteins
As mentioned before, STAT3 is directly or indirectly involved in upor down-regulation of the expression level of a cascade of proteins
(Bousoik and Montazeri Aliabadi, 2018). Activation of STAT3 results in
overexpression of several antiapoptotic proteins, including Mcl-1 (Liu
et al., 2003), Bcl-2 (Gao et al., 2005), and Bcl-XL (Verma et al., 2010),
which contributes to survival of cancer cells and to their resistance to
chemotherapy. The effect of siRNA silencing of selected proteins in
JAK/STAT pathway on expression of these antiapoptotic proteins was
examined using Real-time PCR and Western blot and the results are
summarized in Fig. 4. PCR experiments were performed in selected
TNBC cell lines. In MDA231 cells, individual silencing of STAT3 did not
affect the expression of Bcl-2 or Bcl-XL at mRNA level (Fig. 4A and

Fig. 4. The effect of Individual and combinatorial silencing of selected proteins in JAK/STAT pathway on expression of selected antiapoptotic proteins (Bcl-2, Bcl-XL,
and Mcl-1). The mRNA expression was determined using RT-PCR in MDA 231 (A) and MDA 468 cells (B). In both cell lines, the drop in mRNA level of all three
antiapoptotic proteins was significantly higher in cells exposed to JAK2/gp130 siRNA combination. Bar graphs represent the mean values (n = 3), and the error bars
show the standard deviation. The effect of single and combinational silencing of gp130 and JAK2 on Bcl2 and Mcl-1 at protein level was confirmed by western
blotting (C) in MDA 231 cells. β-actin served as endogenous protein. A similar trend was noted at the protein level (D). Expression of antiapoptotic related molecules
was normalized to untreated cells (NT). Bar graph represents the mean values (n = 3), and the error bars show the standard deviation. Asterisks indicates significant
difference compared to all other study groups (one-way ANOVA, Tukey post-hoc test; p < 0.05).
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response overall (Fig. 4B and Supplementary Table 4); however, a
similar trend was noted, with a few exceptions. Silencing STAT3 indi
vidually showed a moderate effect on mRNA level of all three selected
antiapoptotic proteins (⁓ 40% decrease for three proteins). Silencing
importin α3, however, showed a significant drop in mRNA level of all
three proteins (19, 31, 40% mRNA levels compared to NT group for Bcl1, Bcl-XL, and Mcl-1, respectively). This could be due to a decrease in pSTAT3 translocation to the nucleus, which is required for the over
expression of these downstream proteins. Silencing JAK2 and gp 130
also showed significant downregulating effect on a sub-set of the
selected antiapoptotic proteins: targeting gp 130 reduced mRNA levels
of Bcl-2 and Bcl-XL to 40 and 61% of NT group, respectively, with no
effect on Mcl-1 expression; and silencing JAK2 decreased mRNA level of
Bcl-XL to ⁓30% of not treated cells and showed a mild effect (⁓22%
decrease) on the expression of the other two selected proteins (Fig. 4B
and Supplementary Table 4). In both cell lines, the drop in mRNA level
of all three antiapoptotic proteins was most significant in cells exposed
to JAK2/gp130 siRNA combination one-way ANOVA, Tukey post-hoc
test; p < 0.05). To confirm our observation at protein level, we also
performed a Western blot experiment on Bcl-2 and Mcl-1 expression
levels in MDA231 cells (Fig. 4C). Again, JAK2 silencing did not show any
decrease in the expression of either of the selected antiapoptotic pro
teins, and gp 130 silencing showed a moderate effect. However, the
combination of JAK2 and gp 130 siRNAs showed a significant down
regulation of both proteins (Fig. 4D and Supplementary Table 5).
Inversely, STAT3 can also downregulate expression of pro-apoptosis
proteins that play a role in apoptosis induction or progression. These
proteins include Fas (Kunigal et al., 2009), BAX (Liang et al., 2011), and
P53 (Niu et al., 2005). It has also been reported that STAT3 activates
miRNA-21, which downregulates PTEN (among other proteins), which
is a tumor suppressor (Iliopoulos et al., 2010; Yang et al., 2010).
Therefore, expression of PTEN and P53 was also examined as a result of
individual and combinatorial silencing of the selected targets. Again,
real-time PCR was used to quantify mRNA levels of PTEN and P53 in
both TNBC cell lines (Fig. 5A and B, respectively and Supplementary

Tables 6 and 7). Individual silencing of STAT3 did not increase the
mRNA levels of PTEN significantly in MDA231 cells; however, the
mRNA level for P53 was increased 1.8-folds. Silencing JAK2 did not
affect the expression of either of the two mRNAs; however, targeting
gp130 or importin α3 individually increased the expression of both
mRNA levels in a range of 1.6- to 2-folds (Fig. 5A and Supplementary
Table 6). While combining JAK2 siRNA with STAT3 or importin α3 did
not enhance the observed effect on upregulation of PTEN or P53,
JAK2/gp130 combinatorial silencing did increase mRNA levels ⁓2.2and 3.2-folds for PTEN and P53, respectively.
Again, the magnitude of change in mRNA levels was more significant
in MDA468; however, there were also some discrepancies noted be
tween the two cell lines. For example, silencing gp130 or Importin α3
individually did not increase the mRNA level of either PTEN or P53,
significantly. Also, combination of JAK2 with importin α3 did not show
any enhanced changes in the mRNA levels. STAT3 individual silencing
increased PTEN and P53 mRNA levels ⁓1.3- and 3.7-folds, respectively,
which was a more significant upregulation compared to the effect
observed in MDA231 cells. Most remarkably, the mRNA levels of PTEN
and P53 increased ⁓6.4- and 4.8-folds as a result of JAK2/gp130
simultaneous silencing (Fig. 5B and Supplementary Table 7). Overall,
the mRNA levels of both PTEN and P53 proteins showed the most sig
nificant increase in both cell lines after simultaneous silencing of JAK2/
gp130 (one-way ANOVA, Tukey post-hoc test; p < 0.05). We also per
formed Western Blot analysis of the two selected pro-apoptosis proteins
in MDA231 cells, and the results are presented in Fig. 5C. The over
expression of PTEN and P53 proteins was more significant at protein
level compared to our observation in PCR assays. Both PTEN and P53
proteins were overexpressed in cells treated with JAK2 siRNA (⁓ 2- and
4-folds, respectively) or gp 130 siRNA (⁓ 3- and 5-folds, respectively);
however, the overexpression was at ⁓ 6- and 8-folds for the two selected
proteins, respectively, for the cells exposed to JAK2/gp 130 siRNA
mixture (Fig. 5D and Supplementary Table 8). It is noteworthy that a
similar trend was observed in both experiments: P53 seemed to show
more overexpression in different study groups overall, and the

Fig. 5. The effect of Individual and combinatorial silencing of selected proteins in JAK/STAT pathway on expression of selected pro-apoptotic proteins (PTEN and
p53). The mRNA expression of the pro-apoptotic proteins was determined using RT-PCR in MDA-MB-231 (A) and MDA-MB-468 cells (B). The mRNA levels of both
PTEN and P53 proteins showed the most significant increase in both cell lines after simultaneous silencing of JAK2/gp 130. Bar graphs represent the mean values (n
= 3), and the error bars show the standard deviation. Th effect of single and silencing of gp130 and JAK2 on PTEN and P53 at protein level was confirmed by western
blotting in MDA 231 cells (C). β-actin served as endogenous protein. A similar trend was noted at the protein level (D). Expression of pro-apoptosis proteins was
normalized to untreated cells (NT). Bar graph represents the mean values (n = 3), and the error bars show the standard deviation. Asterisks indicates significant
difference compared to all other study groups (one-way ANOVA, Tukey post-hoc test; p < 0.05).
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combination of JAK2/gp 130 enhanced the effect of silencing on these
downstream proteins compared to individual silencings.
Another protein known to be overexpressed as a result of STAT3
activation is Cyclin D1 protein (Yu et al., 2007; Sinibaldi et al., 2000),
which is a regulator of cell cycle (G1 to S phase progression) and is
linked to progression of cancer (Alao, 2007). Cyclin dependent kinase 4
(CDK4) is one of the binding partners of cyclin D1, which form active
complexes that promote cell cycle progression (Lundberg and Wein
berg, 1998). Therefore, to explore the effect of interference with
JAK/STAT pathway on cell cycle progression, we explored the expres
sion of cyclin D1 and CDK4 at mRNA level in the same study groups. In
MDA231 cells, expression of Cyclin D1 was unchanged or only slightly
affected in most of the study groups. Silencing gp 130 and combination
of JAK2 and STAT3 siRNAs reduced the mRNA level of Cyclin D1 to ⁓
60% compared to NT group. Again, combinatorial silencing of
JAK2/gp130 showed the most significant effect on Cyclin D1 expression
in this cell line by reducing the mRNA level to 45% (one-way ANOVA,
Tukey post-hoc test; p < 0.05; Fig. 6A and Supplementary Table 9).
Among the selected study groups, only individual silencing of importin
α3 and combinations of JAK2/gp 130 and JAK2/importin α3 had a
significant effect on expression of CDK4 mRNA. One-way ANOVA did
not show a significant advantage for JAK/gp 130 combination over the
other two study groups in reducing CDK4 mRNA levels.
Once again, a more significant response was observed in MDA468
cells, where all study groups showed a mild to strong effect on Cyclin D1
and CDK4 mRNA levels. However, the general trend was similar. For
Cyclin D1 expression, individual silencing of importin α3 and the three
selected combinations showed a more significant effect, and combina
torial silencing of JAK2/gp130 showed the most significant effect (only
7% mRNA expression compared to NT group) as it was observed in
MDA231 cells (one-way ANOVA, Tukey post-hoc test; p < 0.05; Fig. 6B
and Supplementary Table 10). Individual silencing of gp 130 or importin
α3 and combinations of JAK2/gp 130 and JAK2/importin α3 had the
most significant effect on CDK4 mRNA level, and One-way ANOVA did
not reveal a significant difference between JAK/gp 130 combination and

the other study groups. Overall, silencing JAK2/gp/130 combination
was again advantageous over other selected studies in terms of Cyclin
D1 expression. This distinction was not significant for CDK4 expression
level.
3.4. Cell viability
As discussed before, one of major roles for JAK/STAT pathway is the
effect on cell proliferation and survival. We, however, explored the ef
fect of individual and combinational silencing of JAK2 and gp 130 on
cell viability in both selected cell lines using CCK-8 assay at different
time points (24, 48, and 72 h after exposure to siRNA). This method uses
a water-soluble tetrazolium salt, which eliminates the error introduced
in this type of assay due to necessity to remove the medium to quantify
the live cells (and therefore a sub-population of cells that are tempo
rarily detached) and replace it with an organic solvent (e.g., DMSO).
Lipofectamine® has been reported to be quite toxic in specific cell
lines, e.g., HELA cells (Kulkarni et al., 2017). We previously reported a
less significant toxicity in breast cancer cells (⁓ 80, 77, and 70% in
MDA-MB-231, MDA-MB-468, and AU565 cells, respectively) (Mozaffari
et al., 2019). The cytotoxicity of the Lipofectamine/siRNA complexes in
MDA231 and MDA468 cell lines were consistent with those results. In
both cell lines, silencing JAK2 and/or gp 130 resulted in a significant
drop in cell viability compared to NT cells and cells exposed to Lip
ofectamine/CsiRNA (Fig. 7).
In MDA231 cells and at 24 h time point, silencing gp 130 or com
bination of JAK2 and gp 130 siRNAs showed a more enhanced effect on
cell viability compared to JAK2 silencing (32.6 and 29.4% viability,
respectively, compared to 48.2% for JAK2 silencing; all percentages are
normalized based on NT study group); however, there was no significant
difference between gp130 individual silencing and JAK2/gp 130 com
bination at this time-point. Also, there was no significant difference in
the effect on cell viability among the three study groups included (JAK2,
gp 130, and JAK2/gp130 silencing) at 48 h time-point. After 72 h of
exposure to siRNA(s), the JAK2/gp 130 combinatorial silencing
Fig. 6. The effect of Individual and combinatorial silencing of
selected proteins in JAK/STAT pathway on expression of
selected cell cycle regulators (Cyclin D1 and CKD4). The mRNA
expression of the cell cycle regulators was determined using
RT-PCR in MDA 231 (A) and MDA 468 cells (B). Silencing
JAK2/gp/130 combination showed a more significant effect on
reducing Cyclin D protein compared to all other selected study
groups. However, the same trend was not observed for CDK4
expression. Asterisks indicates significant difference compared
to all other study groups (one-way ANOVA, Tukey post-hoc
test; p < 0.05). Bar graphs represent the mean values (n =
3), and the error bars show the standard deviation.
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Fig. 7. The effect of individual and combinational silencing of JAK2 and gp 130 on cell viability in MDA 231 (A) and MDA 468 cells (B) was evaluated using CCK-8
assay at different time points. JAK2/gp 130 siRNA combination showed a more significant effect on cell viability compared to individual silencing of the two proteins
at all time points in MDA 468 cells and at 72 h time-point in MDA 231 cells. Data are expressed as percentage of viable cells compared to untreated cells (NT; not
shown). Asterisks indicates significant difference with both individual silencing study groups and ‡ indicates significant difference with JAK2 silencing only (one-way
ANOVA, Tukey post-hoc test; P ˂ 0.05).

significantly enhanced the effect on cell viability compared to the in
dividual silencing of these two targets (8% viable cells for combination
of siRNAs vs. 33.7 and 25.7% viability for JAK2 and gp 130 silencing,
respectively; one-way ANOVA, Tukey post-hoc test; p < 0.05; Fig. 7A).
This general trend was also observed in MDA468, where JAK2/gp

130 siRNA combination showed more efficient in lowering cell viability
compared to individual silencing of the two proteins; however, the dif
ference in effect on viability was significant for all three selected timepoints (one-way ANOVA, Tukey post-hoc test; p < 0.05). One noted
difference in this cell line was lower efficiency of gp 130 silencing in

Fig. 8. The effect of individual and combinational silencing of JAK2 and gp 130 on cell migration in MDA 231 and MDA 468 cells. Microscopic images of the gap
created in cell culture in MDA 231(A) and MDA48 cells (C) using scratch method at different time points show the effect of protein silencing on the rate of gap
closure. The percentage of closure in MDA 231 (B) and MDA 468 (D) cells at different time points (calculated using image J) showed that in both cell lines
combinational silencing of JAK2 and gp 130 was significantly more efficient in reducing migration at 48 h time-point. Asterisks indicate significant difference with
individual silencing groups (one-way ANOVA, Tukey post-hoc test; P ˂ 0.05). The error bars indicate standard deviation (n = 3).
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To test this hypothesis, we performed a differential protein extrac
tion to evaluate the nuclear and cytoplasmic expression level of STAT3
and p-STAT3 in these two subcellular compartments in MDA231 cells.
We used GAPDH and Histone H3 as cytoplasmic and nuclear markers,
respectively, to ensure efficient isolation of the two compartments and
to normalize the intensity of the bands for the calculations.
Cytoplasmic compartment. P-STAT3 levels in cytoplasm were negli
gible compared to total STAT3 levels (Fig. 9A). This is expected since the
phosphorylated STAT3 is dimerized (mostly as homodimers, but also as
heterodimer with STAT1 (Levy and Darnell, 2002)) and translocated to
nucleus. The total STAT3 levels in cytoplasm dropped most significantly
as a response to silencing STAT3. This is also expected, as the siRNA used
directly targeted STAT3 mRNAs. JAK2 and gp 130 had a moderate and
significant effect on STAT3 expression level, respectively (approxi
mately 69 and 29% expression compared to not treated cells). This was
somewhat unexpected, since we are not aware of any studies that report
a downregulation of STAT3 expression as a result of silencing JAK2 or gp
130. However, since the antibody used for STAT3 also detects phos
phorylated STAT3, the bands for STAT3 represent total protein (phos
phorylated and non-phosphorylated). Therefore, the differences
observed might be partially due to change in the level of STAT3 phos
phorylation. Interestingly, combinatorial silencing of JAK2/gp 130 had
an enhanced effect on level of STAT3 in cytoplasm (⁓ 10% compared to
not treated cells; Fig. 9B).
Nuclear compartment. On the other hand, both total STAT and pSTAT3 levels were affected in nuclear compartment (Fig. 9C). Even
though non-phosphorylated STAT3 might translocate into nucleus via
the same transporter (importin α3) (Liu et al., 2005), the expected levels
of non-activated STAT3 are much smaller than the p-STAT3. The total
STAT3 levels were reduced significantly all study groups, with the most
significant drop observed with STAT3 silencing. However, since the
purpose of this study was to evaluate the STAT3 activation level, we
focused on p-STAT3 levels in nuclear compartment. Silencing JAK2, or
gp 130 individually decreased the p-stat3 levels in nucleus more
significantly than silencing STAT3 (⁓ 24 and 29% expression for JAK2
and gp 130 individual silencing, respectively, as compared to ⁓ 82%
expression after STAT3 silencing). This can be explained as STAT3
silencing only reduces the expression of STAT3, which has an indirect
effect on the levels of phosphorylated form of the protein (p-STAT3).
However, both gp 130 and JAK2 are upstream proteins that directly
affect the activation of STAT3 and therefore, silencing either of the two
proteins is expected to lower the level of p-STAT3 in nucleus. Interest
ingly, combination of JAK2/gp 130 siRNAs enhanced this effect and
lowered the level of p-STAT in nucleus to ⁓ 9% compared to not treated
cells (NT; Fig. 9D). This confirms the enhanced effect of combinatorial
silencing of JAK2/gp 130 on the activation of STAT3 compared to the
effect of individual silencing of those proteins, which also could explain
our observations in Figs. 4 - 8.

lowering cell viability compared to JAK2 siRNA. However, this differ
ence was not significant for all three time-points.
3.5. Cell migration
The ability of a cancer cell to migrate allows a change in position
within the tissues, which could lead to dissemination into blood and/or
lymph circulation, and then metastatic growth in distant organs
(Chambers et al., 2002). The signaling pathways contributing to his
migration have been extensively studied. In 2004, Andl et al. reported
JAK-dependent involvement of STAT1 and STAT3 (via EGFR signaling)
in increasing migration of primary esophageal keratinocytes (Andl et al.,
2004). A similar role in cell motility and invasion was later reported in
mouse embryonic fibroblasts (Teng et al., 2009) and Mesenchymal stem
cells (Gao et al., 2009). Therefore, we used a simple scratch test to
evaluate the potential enhanced effect of combinatorial silencing of
JAK2/gp130 on cell migration.
Fig. 8A presents microscopic images of the gap created in cell culture
in MDA231 cells using scratch method at different time points. Using
scrambled siRNA (CsiRNA) as a negative control, the gap clearly started
to close rapidly and was ⁓ 33 and 60% closed after 24 and 48 h,
respectively. Silencing gp 130 and JAK2 individually, reduced the
closure to 14 and 19% at 24 h, and 18 and 24% for 48 h time-point,
respectively. The percentage of closure for the cells treated with
JAK2/gp 130 siRNA mixture, however, was reduced to ⁓ 7 and 9% for
24 and 48 h time-points, respectively. While the difference in the per
centage of closure for JAK2/gp 130 combination with the individual
silencing study groups was not significant after 24 h exposure, one-way
ANOVA showed a significant difference in this effect for combinatorial
silencing at 48 h time-point (Tukey post-hoc test; p < 0.05; Fig. 8B).
The overall trend of effect on cell migration was similar in MDA468
cells (Fig. 8C). The rate of closure was even faster for MDA468 cells
exposed to scrambled siRNA compared to MDA231 cells (⁓ 57% after
24 h; Students’ T-test, P < 0.05); however, at 48 h time-point, the gap
created in cell culture was ⁓ 64% closed, which was not significantly
different with our observation in MDA231 cells (Students’ T-test, P =
0.55). After 24 h exposure to gp 130 or JAK2 siRNA individually, per
centage of closure was ⁓ 17 and 10%, respectively. This percentage was
increased to ⁓ 21 and 20% after 48 h of exposure, respectively. Overall,
JAK2 was more effective in reducing the percentage of closure in the gap
in the culture of MDA468 cells at 24 h time-point, but the difference
between the effect in two cell lines was not significant after 48 h of
exposure. There was no significant difference between the efficiency of
individual gp 130 silencing on the cell migration in the two selected cell
lines. Again, combinatorial silencing of JAK2/gp 130 reduced the per
centage of closure to ⁓ 5 and 6% after 24 and 48 h of exposure,
respectively, which was not significantly different with individual
silencing study groups at 24 h time-point but was significantly more
efficient in reducing migration at 48 h time-point (one-way ANOVA
Tukey post-hoc test; p < 0.05; Fig. 8D).

4. Conclusion

3.6. STAT3 activation

Combinatorial silencing of more than one protein via RNAi ap
proaches can be used as an investigational tool to reveal more efficient
combination therapies in cancer treatment. In this study, we selected
JAK/STAT signaling pathway as one of major intracellular signaling
cascades in different cancer types. While small molecules inhibiting
JAK2 and STAT3 have been studied extensively and even have been
approved by FDA for clinical use, the crosstalk among the proteins
involved in other signaling cascades with this pathway (specifically
JAK2 and STAT3 (Bousoik and Montazeri Aliabadi, 2018)) and the
plasticity of cancer cells that enables them to activate the downstream
proteins of the pathway, make it difficult to effectively shut down this
crucial mechanism in enhanced cell survival and proliferation (and that
is presumably true for other pathways as well). In this study, we
explored combining JAK2 siRNA with siRNAs targeting three other
proteins involved in this signaling pathway. Obviously, the goal of the

The data presented in Figs. 4 - 8 might seem surprising at first, since
they suggest simultaneous silencing of JAK2/gp 130 might have an
enhanced effect on downstream proteins compared to silencing STAT3,
which is directly responsible for adjustments in the transcription of these
proteins (e.g., B-cl2, Bcl-XL, Mcl-1, PTEN, P53, cyclin D1, and CDK4). It
is noteworthy that while silencing STAT3 might have a more significant
effect on the level of expression of STAT3, compared to silencing up
stream proteins (e.g., JAK2 or gp 130), it does not necessarily have a
similar effect on the level of activated form of STAT3 (i.e., serotonin 727
phosphate STAT3, or p-STAT3). Therefore, one possible hypothesis to
explain these findings is that JAK2/gp 130 combinatorial silencing has a
more enhanced effect on p-STAT3 levels compared to individual
silencing of STAT3, JAK2, or gp 130.
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Fig. 9. The effect of silencing STAT3 and the individual and combinational silencing of JAK2 and gp 130 on STAT3 activation in MDA 231 cell line using differential
Western Blotting on cytoplasmic and nuclear compartments. GAPDH and Histone H3 levels were analyzed as cytoplasmic and nuclear markers, respectively, which
indicated effective isolation of the sub-cellular compartments. The bands representing STAT3 show total STAT3 levels (phosphorylated and non-phosphorylated). (A)
Western blot showing the cytoplasmic expression level of STAT3 and p-STAT3. The expression of p-STAT3 was negligible in cytoplasm compared to the total STAT3
levels. (B) Bar graph represents the cytoplasmic expression level of STAT3 in different study groups (n = 3; error bars represent standard deviation). The STAT3 levels
in cytoplasm dropped most significantly as a response to silencing STAT3. (C) Differential western blot shows the nuclear expression level of STAT3 and p-STAT3. The
effect of silencing is apparent on both total STAT3 and the p-STAT3 levels. (D) Bar graph shows nuclear protein levels of p- STAT3 in different study groups (n = 3;
error bars represent standard deviation). The drop in level of p-STAT in nucleus was most significant in cells exposed to JAK2/gp130 siRNA combination.

study was not to identify new targets, but rather confirming the idea of
the potential benefits of combinatorial silencing. While combining the
siRNAs did not enhance the silencing effect on any of the targeted
proteins, simultaneous silencing of JAK/gp 130 showed superior effect
in blocking the pathway compared to individual silencing and other
selected combinations, which was reflected in the expression of selected
downstream proteins. Increased effect on cell survival and migration
also confirmed the efficiency of this combinatorial approach. The level
of STAT3 phosphorylation was also effectively reduced via this combi
natorial silencing compared to silencing STAT3, JAK2, or gp 130. While
we have not tested this hypothesis in this present study, suppressor of
cytokine signaling 3 (SOCS3) might be involved in the observations
reported here. The expression of SOC3 is induced by JAK/STAT
signaling, which triggers the binding of this protein to gp130 and inhi
bition of JAK1, JAK2, and TYK2 (but not JAK3), which results in inhi
bition of STAT3 (Carow and Rottenberg, 2014; Babon et al., 2014;
Babon and Nicola, 2012). This sort of study using nucleic acids facili
tates targeting virtually any selected protein; however, the findings are
applicable to combinational cancer treatment strategies, regardless of
the molecules used to target the proteins. For example, although no
small molecule drug inhibiting gp 130 is used in clinics today (SC144 is

an investigational orally active small molecule gp130), this study shows
the superior efficiency of simultaneous targeting gp 130 and JAK2 in
blocking JAK2/STAT3 pathway, which can be used as a therapeutic
approach in future. But more importantly, this study shows the potential
applications of combinatorial proteins silencing, which can be used in a
larger scale (e.g., screening libraries of siRNA and high-throughput RNA
sequencing) to identify novel targets in future combinational anticancer
therapies.
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